A metabolite of a structural analog of thalidomide lacks teratogenic effect in pregnant rhesus monkeys

Area of Science:

• Pharmacology
• Toxicology
• Developmental Biology

Background:

• CG 3033 is a structural analog of thalidomide.
• A key metabolite, EM 240, is formed by hydrolysis in humans but not in nonhuman primates.
• Understanding metabolite teratogenicity is crucial for drug safety assessment.

Purpose of the Study:

• To evaluate the teratogenic potential of the CG 3033 metabolite, EM 240.
• To assess the relevance of nonhuman primate models for predicting human teratogenic risk of CG 3033 metabolites.

Main Methods:

• Pregnant rhesus monkeys were administered 15 mg/kg of EM 240 orally.
• Dosing occurred throughout the organogenesis period.
• Embryotoxicity and malformations were monitored.

Main Results:

• Oral administration of EM 240 did not result in any evidence of embryotoxicity.
• No teratogenic malformations were observed in the offspring of treated rhesus monkeys.
• The absence of the hydrolysis pathway in nonhuman primates was confirmed.

Conclusions:

• The CG 3033 metabolite EM 240 does not exhibit teratogenic potential in rhesus monkeys.
• Results suggest that nonhuman primates may not be suitable models for assessing the teratogenicity of this specific metabolite due to metabolic pathway differences.
• Further investigation into human-specific metabolic pathways is warranted for thalidomide analogs.